11:45 AM EDT, 04/04/2025 (MT Newswires) -- Bausch + Lomb ( BLCO ) will report first-quarter results on April 30.

RBC is forecasting first-quarter revenue of US$1.15 billion, and adjusted EBITDA of US$161 million. Analyst Douglas Miehm expects the focus to be on the company's DED Rx drugs (Miebo/Xiidra), the impact and resolution timelines of the IOL recall and potential tariff related headwinds following Reciprocal Tariffs announced by the U.S.

The first quarter will continue to be influenced by FX headwinds (RBCe: US$24 million for Q1) which have moderated. Miehm estimates US$45 million for CY25 based on the current exchange rates compared with US$100 million previously.

Lowering target to US$17 from US$18 on revised estimates and updated multiples. Maintain Outperform.

Price: 17.25, Change: -1.03, Percent Change: -5.63